| The COVID‐19 epidemic TP Velavan, CG Meyer Tropical medicine & international health 25 (3), 278, 2020 | 4115 | 2020 |
| Mild versus severe COVID-19: Laboratory markers TP Velavan, CG Meyer International Journal of Infectious Diseases 95, 304-307, 2020 | 707 | 2020 |
| Swarm learning for decentralized and confidential clinical machine learning S Warnat-Herresthal, H Schultze, KL Shastry, S Manamohan, ... Nature 594 (7862), 265-270, 2021 | 609 | 2021 |
| Host-directed therapies for infectious diseases: current status, recent progress, and future prospects A Zumla, M Rao, RS Wallis, SHE Kaufmann, R Rustomjee, P Mwaba, ... The Lancet Infectious Diseases 16 (4), e47-e63, 2016 | 309 | 2016 |
| Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible LA Nikolai, CG Meyer, PG Kremsner, TP Velavan International Journal of Infectious Diseases 100, 112-116, 2020 | 255 | 2020 |
| A global metagenomic map of urban microbiomes and antimicrobial resistance D Danko, D Bezdan, EE Afshin, S Ahsanuddin, C Bhattacharya, DJ Butler, ... Cell 184 (13), 3376-3393. e17, 2021 | 226 | 2021 |
| Emergence of new SARS-CoV-2 Variant of Concern Omicron (B. 1.1. 529)-highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine … E Petersen, F Ntoumi, DS Hui, A Abubakar, LD Kramer, C Obiero, ... International Journal of Infectious Diseases 114, 268-272, 2022 | 200 | 2022 |
| Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19 B Krämer, R Knoll, L Bonaguro, M ToVinh, J Raabe, ... Immunity 54 (11), 2650-2669. e14, 2021 | 180 | 2021 |
| Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environment KR Chng, C Li, D Bertrand, AHQ Ng, JS Kwah, HM Low, C Tong, ... Nature medicine 26 (6), 941-951, 2020 | 177 | 2020 |
| Host genetic factors determining COVID-19 susceptibility and severity TP Velavan, SR Pallerla, J Rüter, Y Augustin, PG Kremsner, S Krishna, ... EBioMedicine 72, 2021 | 173 | 2021 |
| Monkeypox 2022 outbreak: an update TP Velavan, CG Meyer Trop Med Int Health 27 (7), 604-605, 2022 | 152 | 2022 |
| Parasite infection, carcinogenesis and human malignancy H Van Tong, PJ Brindley, CG Meyer, TP Velavan EBioMedicine 15, 12-23, 2017 | 146 | 2017 |
| Occult hepatitis B virus infection in Nigerian blood donors and hepatitis B virus transmission risks OO Oluyinka, HV Tong, SY Bui Tien, AH Fagbami, O Adekanle, ... PloS one 10 (7), e0131912, 2015 | 123 | 2015 |
| Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia SK Mekonnen, A Aseffa, N Berhe, T Teklehaymanot, RM Clouse, T Gebru, ... Malaria journal 13, 1-9, 2014 | 110 | 2014 |
| 2019-nCoV in context: lessons learned? RA Kock, WB Karesh, F Veas, TP Velavan, D Simons, LEG Mboera, O Dar, ... The Lancet Planetary Health 4 (3), e87-e88, 2020 | 103 | 2020 |
| The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance H Tegally, JE San, M Cotten, M Moir, B Tegomoh, G Mboowa, DP Martin, ... Science 378 (6615), eabq5358, 2022 | 96 | 2022 |
| Hepatitis E: An update on One Health and clinical medicine TP Velavan, SR Pallerla, R Johne, D Todt, E Steinmann, M Schemmerer, ... Liver International 41 (7), 1462-1473, 2021 | 94 | 2021 |
| Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers P Kremsner, P Mann, J Bosch, R Fendel, JJ Gabor, A Kreidenweiss, ... MedRxiv, 2020.11. 09.20228551, 2020 | 94 | 2020 |
| Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial PG Kremsner, P Mann, A Kroidl, I Leroux-Roels, C Schindler, JJ Gabor, ... Wiener Klinische Wochenschrift 133 (17), 931-941, 2021 | 93 | 2021 |
| Codiversification of gut microbiota with humans TA Suzuki, JL Fitzstevens, VT Schmidt, H Enav, KE Huus, ... Science 377 (6612), 1328-1332, 2022 | 91 | 2022 |
